Functional outcomes with esketamine in treatment-resistant depression: A 6-month multicenter real-world study.
European psychiatry : the journal of the Association of European Psychiatrists June 10, 2026 Riccardo Guglielmo, Miriam Olivola, Alberto Inuggi et al.
Esketamine has demonstrated efficacy in treatment-resistant depression (TRD), but medium-term real-world functional outcomes remain understudied. This study described 6-month depressive symptoms and functional trajectories during routine esketamine treatment, focusing on functional outcomes and remission correlates. In this prospective multicenter study, 60 patients with TRD initiating...